contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


zelluna-asa-new-share-capital-registered-1

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Zelluna är ett norskt läkemedelsbolag. Bolagets affärsinriktning är att utveckla immunoterapier mot diverse cancertillstånd. Forskning och utveckling utgår ifrån egenbaserad teknologisk plattform, där produkterna huvudsakligen vidareutvecklas som vaccin. Störst närvaro återfinns inom Europa och Nordamerika. Bolaget grundades under 2011 och har sitt huvudkontor i Oslo, Norge.

Zelluna

Oslo, Norway, 8 December, 2025: Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement of 5,500...

Oslo, Norway, 8 December, 2025: Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement of 5,500,000 new shares (the "Private Placement"), divided on a first tranche of 3,729,774 new shares and a second tranche of 1,770,226 new shares ("Tranche 2"), and the allocation of 315,639 new shares in the retail offering carried out via the PrimaryBid platform. The share capital increase pertaining to the issuance of the 1,770,226 new shares in Tranche 2 has now been registered with the Norwegian Register of Business Enterprises. The Company's new share capital is NOK 26,269,801 divided into 26,269,801 shares, each with a par value of NOK 1. For further information, please contact: Namir Hassan, CEO, Zelluna ASA Email:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=WjcuTb3PC88Rc_wBo5q4ypRSnuI5BXsmdGSoqxiAQM1m7G_ygHsyjm3fdnXR68OeOhuG0iB4JzON4PYcDBc-_Un2-WkLy0hP97F4v9jAvatkkXbv7HHniYp8iW0HfjRT1KzVU8izzJNUGOxdMNB95EEeW6QvAY1Luy50xAtNhXS30MprZ3x-4aO71Z0GcTzDMcpqCwa2isY2m9W15Wfvns_hDRfZctvB1b4cMzhkTpuVgY3bE6rBkbMZhAf_o-g5XfCJiSpsBO_1HcpLUZnXu57eG72Bhnw-TSiARCfPV5s=">namir.hassan@zelluna.com</a> Phone: +44 7720 687608 Hans Vassgård Eid, CFO, Zelluna ASA Email:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=oQkCEJKlqI489bfOy_eIzM_kMG63h0hqssgiSs_BMRBEX7LA2dKbg1-tbHkkflqiISd0YxocDbnGtIEjUuS3n98cAl6J0R4xTZfSsW5glFVTG-0X_UmUmVjrMzT7uvUX7jeHALT4HnPFFu5xh9_qTjZlNb0TQGsXVj2wKKjPKfM1DiF_3Nl2aAZBAq8Rq90-oYeubPqDtC6aZu7ukQbh1EngYAo19uuT3p2E8B-5O1JrAMDdSzgMA89gD68Zbyu1Ob0kuD7p_8GwnVMemUcFeIKcu2S3TLDNWaOSCEk6hNg=">hans.eid@zelluna.com</a> Phone: +47 482 48632 About Zelluna ASA Zelluna ASA (OSE: ZLNA) is a biotechnology company pioneering the development of allogeneic ‘off-the-shelf’ T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of cancer. The company’s platform combines the innate killing power of NK cells with the precision targeting of TCRs, designed to address the limitations of current cell therapies, particularly in solid tumours. Zelluna’s proprietary manufacturing process enables scalable, cost-effective production of TCR-NK cell therapies, with potential for broad patient accessibility. The company’s lead program, ZI-MA4-1, targets the MAGE-A4 tumour antigen and is expected to enter clinical trials in 2026. Zelluna is headquartered in Oslo, Norway. <img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE0MzY4NyM0MDIyNzk3OTcjMjIwOTM5Mw==" alt=""> <img src="https://ml-eu.globenewswire.com/media/YjMyYzRjMzQtY2U1NC00NjlkLWExMDAtNTkyMTU2OGU3ZGIzLTEyMjA5NDYtMjAyNS0xMi0wOC1lbg==/tiny/Zelluna-ASA.png" alt="">